About us


Savira pharmaceuticals GmbH was founded in July 2009 by the European Molecular Biology Laboratory (EMBL), onepharm Research and Development GmbH, private investors, and management. Led by CEO Oliver Szolar and CSO Helmut Buschmann, a seasoned management team combines scientific, technological, and business experience in the pharmaceutical industry.

Savira follows the biotech business model, turning capital and public grants into the preclinical and clinical development of a portfolio of anti-influenza drug candidates. Savira thus strives to create a sustainable pipeline, generate value for shareholders, improve quality of life for people suffering from influenza, and add to the arsenal of antivirals thus improving influenza pandemic preparedness.